PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758045
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758045
Global Blood Plasma Market to Reach US$51.5 Billion by 2030
The global market for Blood Plasma estimated at US$32.9 Billion in the year 2024, is expected to reach US$51.5 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Human Plasma Source, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$35.7 Billion by the end of the analysis period. Growth in the Synthetic Plasma Source segment is estimated at 5.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$9.0 Billion While China is Forecast to Grow at 12.4% CAGR
The Blood Plasma market in the U.S. is estimated at US$9.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.1 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.
Global Blood Plasma Market - Key Trends & Drivers Summarized
Why Is Blood Plasma Considered a Critical Component in Modern Medicine?
Blood plasma, the straw-colored liquid portion of blood, plays a pivotal role in modern medicine due to its rich composition of proteins, antibodies, clotting factors, and electrolytes. Unlike whole blood, which is primarily used for transfusions in trauma cases, plasma is valued for its therapeutic properties and is processed into a wide range of life-saving treatments. These include immunoglobulins for immune deficiencies, albumin for volume expansion in critically ill patients, and clotting factors for individuals with hemophilia and other bleeding disorders. Plasma is also used in treating rare, chronic, and genetic conditions that would otherwise have few viable treatment options. In the wake of rising chronic illnesses, immune system disorders, and global public health emergencies, plasma-derived therapies are becoming more critical than ever. During the COVID-19 pandemic, for example, convalescent plasma drew attention for its potential to transfer antibodies from recovered patients to those battling the virus, highlighting the adaptability and importance of plasma in responding to emerging health threats. Furthermore, the unique nature of plasma-being both a renewable biological resource and a foundational ingredient for biologics-has made it an essential focus for pharmaceutical companies and healthcare providers. The global need for plasma continues to grow, placing immense importance on collection, processing, and equitable distribution systems. As therapeutic applications broaden and demand intensifies, blood plasma is solidifying its status as an irreplaceable pillar of both emergency care and long-term disease management.
How Are Advancements in Plasma Fractionation and Processing Transforming the Industry?
Technological innovations in plasma fractionation-the process by which different therapeutic components are separated from raw plasma-are dramatically enhancing the efficiency, scalability, and safety of plasma-based therapies. Over the years, traditional cold ethanol fractionation methods have evolved into highly specialized, multi-step processes that enable precise extraction of various plasma proteins, including immunoglobulins, albumin, and coagulation factors. Newer techniques such as chromatography and nanofiltration have further increased purity levels while minimizing the risk of viral contamination, improving both patient outcomes and regulatory compliance. These advancements are enabling manufacturers to optimize yield, reduce production costs, and accelerate turnaround times, which is crucial given the global shortage of plasma and increasing demand for its derivatives. Automation and digital tracking are also streamlining quality control, traceability, and inventory management, making the entire value chain more efficient and transparent. In addition to technological progress, collaborations between biopharmaceutical companies and academic research institutions are spurring innovation in developing next-generation plasma-derived therapies that can target a broader range of diseases. Personalized medicine is also becoming a factor, with research into how specific plasma proteins can be tailored or enhanced to suit individual patient needs. As these technologies mature, they are expected to open new possibilities in treating autoimmune disorders, neurological conditions, and rare diseases. Collectively, advancements in processing and production are making plasma therapies more accessible and safer, laying the groundwork for a more robust and responsive global plasma industry.
How Are Global Donation Practices and Ethical Considerations Impacting Supply Chains?
The global blood plasma supply chain is heavily dependent on human donors, making ethical collection practices, donor compensation models, and donation infrastructure pivotal to ensuring a stable and sustainable plasma supply. Currently, the United States dominates global plasma collection, accounting for more than 60% of the total global supply, largely due to its allowance of paid plasma donations-a policy not universally accepted. In contrast, many European countries restrict or prohibit monetary compensation, citing ethical concerns and donor safety, resulting in comparatively lower collection volumes. This has led to a significant supply imbalance, with many countries relying on imported plasma to meet domestic therapeutic needs. These disparities are sparking international debate about best practices for donor recruitment and the morality of commodifying a biological resource. Regulatory bodies such as the World Health Organization (WHO) and the European Medicines Agency (EMA) continue to advocate for voluntary, non-remunerated donations, but the growing global demand for plasma therapies is putting pressure on these principles. To address this challenge, several nations are investing in domestic collection infrastructure, awareness campaigns, and partnerships with nonprofit and private collection agencies. Logistics and cold-chain management also play a vital role, as plasma must be collected, transported, and processed under stringent temperature and timing requirements. Meanwhile, donor safety, transparency, and ethical sourcing remain top concerns for both governments and consumers. Striking a balance between supply chain efficiency, donor rights, and ethical standards is a complex but crucial component of the plasma industry’s future stability.
What Are the Key Factors Driving Growth in the Blood Plasma Market Worldwide?
The growth in the blood plasma market is driven by several interlinked factors spanning demographic trends, technological advancements, healthcare policy changes, and rising global disease burdens. One of the most influential drivers is the growing incidence of chronic and rare diseases that rely on plasma-derived therapies for effective management, including immunodeficiencies, hemophilia, and hereditary angioedema. Aging populations in developed countries are also fueling demand, as older individuals are more likely to suffer from immune dysfunction, surgical recovery needs, and critical illnesses that require plasma products. Additionally, increasing awareness and diagnosis of rare diseases, supported by improved access to specialized healthcare, are expanding the patient pool in need of these therapies. On the technological side, improvements in plasma collection, processing, and storage are enabling manufacturers to scale operations more efficiently, thus meeting growing demand more rapidly. Government policies encouraging domestic plasma collection and public-private partnerships are also playing a role, particularly in countries that historically relied on imports. Furthermore, strong investment from biopharmaceutical companies and a surge in clinical research for plasma-derived treatments are expanding the product pipeline and therapeutic applications. Market growth is also bolstered by evolving reimbursement structures, regulatory approvals, and enhanced global healthcare infrastructure, particularly in emerging economies. Together, these drivers are creating a fertile landscape for continued expansion in the plasma market, underscoring the critical role that plasma-derived products play in the evolving landscape of modern, precision-driven, and life-saving healthcare.
SCOPE OF STUDY:
The report analyzes the Blood Plasma market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Source (Human Plasma Source, Synthetic Plasma Source); Application (Therapeutic Use Application, Diagnostic Use Application, Research & Development Application)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 48 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.